SecBot SecBot
PRESS-RELEASE ·Filed Jun 3, 2026

MNKD

MannKind
NEUTRAL
Impact 5/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Phase 1b data readout in Q3 2026 is the next major catalyst. Monitor for safety/tolerability and pharmacokinetic results that could de-risk the Phase 2 program. No financial guidance or commercial timeline provided.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.36
T+0 close · Jun 3, 2026 · via day close
Latest settled
+20.83%
T+60 · $4.06
Vs SPY
+18.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $3.36entry
  2. T+1 · 6mo ago +4.76%α +4.36% · $3.52
  3. T+5 · 5mo ago +8.04%α +11.86% · $3.63
  4. T+20 · 5mo ago +34.52%α +35.52% · $4.52
  5. T+60 · 3mo ago +20.83%α +18.33% · $4.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enrollment of the first patient in the global Phase 2 INFLO-2 study for nintedanib DPI (MNKD-201) in idiopathic pulmonary fibrosis. Phase 1b data readout is expected in Q3 2026, representing a key clinical milestone for the program.

Key Facts

  • Phase 1b INFLO-1 patient randomization completed; data readout expected Q3 2026
  • First patient enrolled in global Phase 2 INFLO-2 study (target ~210 participants across ~85 sites)
  • Nintedanib DPI (MNKD-201) uses Technosphere dry powder inhalation technology to deliver drug directly to lungs
  • INFLO-2 is a randomized, double-blind, placebo-controlled trial with 12-week treatment period and 24-week open-label extension
  • Primary objective of INFLO-2 is safety and tolerability; secondary includes FVC decline rate

Financial Impact

No financial data provided; program is in early clinical development with no revenue contribution expected near-term

r_and_d_expensepipeline_value

Risk Factors

  • Clinical trial failure risk: nintedanib DPI may not demonstrate adequate safety or efficacy in Phase 2
  • Competition from approved oral nintedanib and other IPF therapies
  • Regulatory and manufacturing risks for inhaled formulation
  • No revenue from this program for several years if successful

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3305858

Track record

17 reports on MNKD

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +20.00% at T+60 after the May 27, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.23 Now $3.96 −6.38% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  3. Nov 5, 202611d ago Press Release Bearish 5/10 Entry $3.90 Now $3.96 −1.54% settles Dec 7
  4. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $3.73 Now $3.96 +6.17% settles Dec 2
  5. Jul 29, 202615w ago Press Release Bullish 6/10 Entry $3.85 to $4.09 Now $3.96 +2.86% ▲ +6.23% +1.21% vs SPY
  6. Jul 24, 202616w ago 8-K Mixed 6/10 Entry $3.95 to $4.07 Now $3.96 +0.25% ▲ +3.04% −0.26% vs SPY
  7. Jul 17, 202617w ago Insider Cluster Neutral 3/10 Entry $3.98 to $3.90 Now $3.96 −0.50% ▼ −2.01% −6.13% vs SPY
  8. Jun 3, 202623w ago Press Release Neutral 5/10 Viewing Entry $3.36 to $4.52 Now $3.96 +17.86% ▲ +34.52% +35.52% vs SPY
  9. Jun 2, 202623w ago 8-K Bullish 7/10 Entry $3.43 to $4.05 Now $3.96 +15.45% ▲ +18.08% +19.64% vs SPY
  10. May 29, 202624w ago Press Release Bullish 8/10 Entry $3.77 to $4.24 Now $3.96 +5.04% ▲ +12.47% +14.26% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (11h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 3, 2026